# Relates to requiring certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

**Bill ID:** S2393B
**Session:** 2023
**Sponsor:** Robert Jackson
**Status:** In Senate Committee

## Summary

Requires certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  2393
 
  2023-2024 Regular Sessions
 
  I N  S E N A T E
 
  January 20, 2023
  ___________
 
 Introduced  by  Sen. JACKSON -- read twice and ordered printed, and when
  printed to be committed to the Committee on Insurance
 
 AN ACT to amend the insurance law, in relation to  requiring  individual
  and  small group insurance carriers and group and blanket accident and
  health carriers to certify that at least a  majority  of  prescription
  drug rebates are provided to patients at the point of sale
 
  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. Paragraph 1 of subsection (e) of section 3231 of the insur-
 ance law, as added by chapter 501 of the laws of  1992,  is  amended  by
 adding a new subparagraph (C) to read as follows:
  (C)  AN  INSURER SHALL ANNUALLY CERTIFY TO THE DEPARTMENT THAT, DURING
 THE PRIOR BENEFIT YEAR, THE INSURER MADE AVAILABLE TO ENROLLEES  AT  THE
 POINT  OF SALE AT LEAST A MAJORITY (I.E., GREATER THAN FIFTY PERCENT) OF
 THE REBATES RECEIVED BY SUCH INSURER OR ANY  THIRD  PARTY  ADMINISTERING
 PRESCRIPTION DRUG BENEFITS ON BEHALF OF SUCH INSURER.
  (I) FOR PURPOSES OF THIS PARAGRAPH, "REBATE" MEANS:
  (1)  NEGOTIATED  PRICE  CONCESSIONS  INCLUDING BUT NOT LIMITED TO BASE
 REBATES AND REASONABLE ESTIMATES OF ANY  PRICE  PROTECTION  REBATES  AND
 PERFORMANCE-BASED  REBATES THAT MAY ACCRUE DIRECTLY OR INDIRECTLY TO THE
 ISSUER DURING THE COVERAGE YEAR FROM A MANUFACTURER, DISPENSING  PHARMA-
 CY, OR OTHER PARTY TO THE TRANSACTION, AND
  (2)  REASONABLE  ESTIMATES  OF ANY FEES AND OTHER ADMINISTRATIVE COSTS
 THAT ARE PASSED THROUGH TO THE ISSUER AND SERVE TO REDUCE  THE  ISSUER'S
 PRESCRIPTION DRUG LIABILITIES FOR THE COVERAGE YEAR.
  (II)  IN PROVIDING THE CERTIFICATION REQUIRED UNDER THIS SUBPARAGRAPH,
 AN ISSUER SHALL SHARE INFORMATION REGARDING THE ACTUAL AMOUNT OF REBATES
 THE ISSUER RECEIVED ON A PRODUCT-,  MANUFACTURER-  OR  PHARMACY-SPECIFIC
 BASIS  WITH  THE  DEPARTMENT  AND  THE AMOUNT THAT WAS PASSED THROUGH TO
 CONSUMERS. ANY INFORMATION  SHARED  UNDER  THIS  SUBPARAGRAPH  SHALL  BE
 CONFIDENTIAL AND NOT SUBJECT TO DISCLOSURE BY THE DEPARTMENT.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD05427-01-3
 S. 2393  2
 
  ยง 2. Subsection (b) of section 3221 of the insurance law is amended to
 read as follows:
  (b)  (1)  No  such policy shall be delivered or issued for delivery in
 this state unless a schedule of the premium  rates  pertaining  to  such
 form shall have been filed with the superintendent.
  (2)  AN  INSURER SHALL ANNUALLY CERTIFY TO THE DEPARTMENT THAT, DURING
 THE PRIOR BENEFIT YEAR, THE INSURER MADE AVAILABLE TO ENROLLEES  AT  THE
 POINT  OF SALE AT LEAST A MAJORITY (I.E., GREATER THAN FIFTY PERCENT) OF
 THE REBATES RECEIVED BY SUCH INSURER OR ANY  THIRD  PARTY  ADMINISTERING
 PRESCRIPTION DRUG BENEFITS ON BEHALF OF SUCH INSURER.
  (A) FOR PURPOSES OF THIS PARAGRAPH, "REBATE" MEANS:
  (I)  NEGOTIATED  PRICE  CONCESSIONS  INCLUDING BUT NOT LIMITED TO BASE
 REBATES AND REASONABLE ESTIMATES OF ANY  PRICE  PROTECTION  REBATES  AND
 PERFORMANCE-BASED  REBATES THAT MAY ACCRUE DIRECTLY OR INDIRECTLY TO THE
 ISSUER DURING THE COVERAGE YEAR FROM A MANUFACTURER, DISPENSING  PHARMA-
 CY, OR OTHER PARTY TO THE TRANSACTION, AND
  (II)  REASONABLE  ESTIMATES OF ANY FEES AND OTHER ADMINISTRATIVE COSTS
 THAT ARE PASSED THROUGH TO THE ISSUER AND SERVE TO REDUCE  THE  ISSUER'S
 PRESCRIPTION DRUG LIABILITIES FOR THE COVERAGE YEAR.
  (B)  IN PROVIDING THE CERTIFICATION REQUIRED UNDER THIS SUBSECTION, AN
 ISSUER SHALL SHARE INFORMATION REGARDING THE ACTUAL  AMOUNT  OF  REBATES
 THE  ISSUER  RECEIVED  ON A PRODUCT-, MANUFACTURER- OR PHARMACY-SPECIFIC
 BASIS WITH THE DEPARTMENT AND THE AMOUNT  THAT  WAS  PASSED  THROUGH  TO
 CONSUMERS.  ANY  INFORMATION  SHARED  UNDER  THIS  SUBPARAGRAPH SHALL BE
 CONFIDENTIAL AND NOT SUBJECT TO DISCLOSURE BY THE DEPARTMENT.
  ยง 3. This act shall take effect immediately.